Prolia pricing sacrafices PMO for Oncology

Quote

Anonymous

Guest
Amgen clearly decided to sacrifice sales in PMO for first or even second line based just on the $1650 per year pricing. Amgen's strategy for Prolio is heavily weighted towards future oncology sales which will sell for 10x-12x the PMO price. The higher the PMO price = much higher oncology price. (Sacrifice PMO sales today = more Oncology revenue later).

This can not be good for the PMO sales force. Does anyone in Wave 1 actually think they will be able to sell this - at this price point? the higher price will offset some of the lost revenue, but not enough to make up for what is likely to be a much lower sales volume than expected. Not good for the PMO salesforce - potentially good news for Amgen and oncology sales force as I think the street will like this strategy.

Good news is no black box on label and most of the warnings on label were widely expected.

Good luck wave I this is going to be a challenge. . . . Given the above I think it is even more unlikely there will be additional hiring of any significance in the PMO space. I think Amgen is gearing up to put its resources behind the oncology opportunity which will be far greater than the PMO opportunity.
 






Anonymous said:
Amgen clearly decided to sacrifice sales in PMO for first or even second line based just on the $1650 per year pricing. Amgen's strategy for Prolio is heavily weighted towards future oncology sales which will sell for 10x-12x the PMO price. The higher the PMO price = much higher oncology price. (Sacrifice PMO sales today = more Oncology revenue later).

This can not be good for the PMO sales force. Does anyone in Wave 1 actually think they will be able to sell this - at this price point? the higher price will offset some of the lost revenue, but not enough to make up for what is likely to be a much lower sales volume than expected. Not good for the PMO salesforce - potentially good news for Amgen and oncology sales force as I think the street will like this strategy.

Good news is no black box on label and most of the warnings on label were widely expected.

Good luck wave I this is going to be a challenge. . . . Given the above I think it is even more unlikely there will be additional hiring of any significance in the PMO space. I think Amgen is gearing up to put its resources behind the oncology opportunity which will be far greater than the PMO opportunity.
Click to expand...


This would be a smart way of doing things especially since analysts are saying Prolia will have a slow start since they are launching into a PCP market which has never prescribed biotech drugs before. Most Drs are no doubt going to wait the year or so of market use before they even attempt to try it. I think if a PCP is interested they will send them to a rheumatologist to get Prolia so they don't have to worry about any liability initially
 






Anonymous said:
Amgen clearly decided to sacrifice sales in PMO for first or even second line based just on the $1650 per year pricing. Amgen's strategy for Prolio is heavily weighted towards future oncology sales which will sell for 10x-12x the PMO price. The higher the PMO price = much higher oncology price. (Sacrifice PMO sales today = more Oncology revenue later).

This can not be good for the PMO sales force. Does anyone in Wave 1 actually think they will be able to sell this - at this price point? the higher price will offset some of the lost revenue, but not enough to make up for what is likely to be a much lower sales volume than expected. Not good for the PMO salesforce - potentially good news for Amgen and oncology sales force as I think the street will like this strategy.

Good news is no black box on label and most of the warnings on label were widely expected.

Good luck wave I this is going to be a challenge. . . . Given the above I think it is even more unlikely there will be additional hiring of any significance in the PMO space. I think Amgen is gearing up to put its resources behind the oncology opportunity which will be far greater than the PMO opportunity.
Click to expand...

When you steal an analysts words you might want to credit the source. The first part of your post if clearly "lifted", so you need to credit it thief.
 






Wait...didn't the agency quiz us on whether we had data on disease progression and that we didn't really design our clinical studies to truly detect progression? The Oncology indication is ways off, especially with ongoing issue about us coming clean about ESAs. Thank you RegSafety for your leadership in this situation.
 






Anonymous said:
Amgen clearly decided to sacrifice sales in PMO for first or even second line based just on the $1650 per year pricing. Amgen's strategy for Prolio is heavily weighted towards future oncology sales which will sell for 10x-12x the PMO price. The higher the PMO price = much higher oncology price. (Sacrifice PMO sales today = more Oncology revenue later).

This can not be good for the PMO sales force. Does anyone in Wave 1 actually think they will be able to sell this - at this price point? the higher price will offset some of the lost revenue, but not enough to make up for what is likely to be a much lower sales volume than expected. Not good for the PMO salesforce - potentially good news for Amgen and oncology sales force as I think the street will like this strategy.

Good news is no black box on label and most of the warnings on label were widely expected.

Good luck wave I this is going to be a challenge. . . . Given the above I think it is even more unlikely there will be additional hiring of any significance in the PMO space. I think Amgen is gearing up to put its resources behind the oncology opportunity which will be far greater than the PMO opportunity.
Click to expand...

Well, I don't know you ill-informed idiot! Reclast is $1500+ a year and it's Novartis fastest growing launch product ever. I know, I launched it 2 1/2 years ago. I'll put this in lamen's terms so you have a slight chance of understanding it...Medicare Part B is the patient that we are going after, just like Reclast. Med B pays 80% of the cost right off the top, then over 90% of Med B pts also have a supplemental coinsurance that picks up almost all of the remaining 20% cost. It's June, an extremely high % of Medicare pts have already met and paid their respective deductibles. So guess what, for the Med B pts (which I stated is the pts that we are going after) will have a co-pay under that of branded orals and real damn close to generic alendronate. Got it? Unbelievable how stupid some people are spouting off. I lived in the Reclast, Med B world for 2 1/2 years and as soon as you get around any kind of paperwork for insurance verification, then the price point isn't that much of an issue for the Med B pts. By the way, our paperwork up front and throughout the process is much more simplified than Reclast for sure. So believe what you will but just know that you are way off base.
 






Anonymous said:
Well, I don't know you ill-informed idiot! Reclast is $1500+ a year and it's Novartis fastest growing launch product ever. I know, I launched it 2 1/2 years ago. I'll put this in lamen's terms so you have a slight chance of understanding it...Medicare Part B is the patient that we are going after, just like Reclast. Med B pays 80% of the cost right off the top, then over 90% of Med B pts also have a supplemental coinsurance that picks up almost all of the remaining 20% cost. It's June, an extremely high % of Medicare pts have already met and paid their respective deductibles. So guess what, for the Med B pts (which I stated is the pts that we are going after) will have a co-pay under that of branded orals and real damn close to generic alendronate. Got it? Unbelievable how stupid some people are spouting off. I lived in the Reclast, Med B world for 2 1/2 years and as soon as you get around any kind of paperwork for insurance verification, then the price point isn't that much of an issue for the Med B pts. By the way, our paperwork up front and throughout the process is much more simplified than Reclast for sure. So believe what you will but just know that you are way off base.
Click to expand...


Hey smartie pants what happens when they need the next injection? OH yea 6 months from JUly is aaaahh wait let me figure it out ..... Thats right Jan- now how many part B pts have made their deductibles then ? Thats right jackoff the answer is 0
 






Anonymous said:
Hey smartie pants what happens when they need the next injection? OH yea 6 months from JUly is aaaahh wait let me figure it out ..... Thats right Jan- now how many part B pts have made their deductibles then ? Thats right jackoff the answer is 0
Click to expand...

Well the Deductible in Jan will be $155 for Med B pts jackoff. Certainly hasn't hurt the Reclast business, I should know as I launched it successfully and you are an idiot!
 






Anonymous said:
Hey smartie pants what happens when they need the next injection? OH yea 6 months from JUly is aaaahh wait let me figure it out ..... Thats right Jan- now how many part B pts have made their deductibles then ? Thats right jackoff the answer is 0
Click to expand...

AGAIN...you are so far off base. Are you a rep in the BHBU because if you are, you don't stand a chance in hell of selling this drug. Perhaps that's why you are bitching.
 






Anonymous said:
Well, I don't know you ill-informed idiot! Reclast is $1500+ a year and it's Novartis fastest growing launch product ever. I know, I launched it 2 1/2 years ago. I'll put this in lamen's terms so you have a slight chance of understanding it...Medicare Part B is the patient that we are going after, just like Reclast. Med B pays 80% of the cost right off the top, then over 90% of Med B pts also have a supplemental coinsurance that picks up almost all of the remaining 20% cost. It's June, an extremely high % of Medicare pts have already met and paid their respective deductibles. So guess what, for the Med B pts (which I stated is the pts that we are going after) will have a co-pay under that of branded orals and real damn close to generic alendronate. Got it? Unbelievable how stupid some people are spouting off. I lived in the Reclast, Med B world for 2 1/2 years and as soon as you get around any kind of paperwork for insurance verification, then the price point isn't that much of an issue for the Med B pts. By the way, our paperwork up front and throughout the process is much more simplified than Reclast for sure. So believe what you will but just know that you are way off base.
Click to expand...

Dumbfuck...Reclast is 1150 per year NOT 1500+ and currently the lowest priced branded drug now in the market. Actonel Boniva are all priced around 1350/Yr/ All branded oral BPs went for a price raise this year EXCEPT reclast. Their strategy is to go for volume pricing and capture as much market share as possible before it becomes generic in 2 years.
 






Anonymous said:
Dumbfuck...Reclast is 1150 per year NOT 1500+ and currently the lowest priced branded drug now in the market. Actonel Boniva are all priced around 1350/Yr/ All branded oral BPs went for a price raise this year EXCEPT reclast. Their strategy is to go for volume pricing and capture as much market share as possible before it becomes generic in 2 years.
Click to expand...

Hey dumbfuck, I f-ing sold reclast and it's not $1150 anymore, especially where I live. They have had two price increases since launch where it was originally priced at around $1150 2 1/2 years ago, dumbass. I have done pharmacy checks and it is priced right at $1400 plus the infusion fees which in my market averages out to be another $75. FU
 












Anonymous said:
Hey dumbfuck, I f-ing sold reclast and it's not $1150 anymore, especially where I live. They have had two price increases since launch where it was originally priced at around $1150 2 1/2 years ago, dumbass. I have done pharmacy checks and it is priced right at $1400 plus the infusion fees which in my market averages out to be another $75. FU
Click to expand...

Ignorant dumb fuck..... what fuckin pharmacy checks you are talking? Reclast AWP is available publicly...redbook, thomson reuters databank etc

just read the comments from one specialist in the article as I am sure you don't have access to any of the shit i mentioned above

http://seekingalpha.com/article/207...ly-to-early-fda-approval-of-osteoporosis-drug
 












What message does this send the troops????????? Keep drinking the kool-aid buddy. Even leadership is talking down expectations!

From Wall Street Journal:

"For its part, Amgen is setting modest near-term expectations for Prolia. "No one is expecting the drug will fly off the shelves," said Roger Perlmutter, Amgen's research chief."
 






Anonymous said:
Hey dumbfuck, I f-ing sold reclast and it's not $1150 anymore, especially where I live. They have had two price increases since launch where it was originally priced at around $1150 2 1/2 years ago, dumbass. I have done pharmacy checks and it is priced right at $1400 plus the infusion fees which in my market averages out to be another $75. FU
Click to expand...

You are an idiot. I don't care where you f-ing sold Reclast but look at the AWP. I have seen bills recently and it is not $1400 like you have said. Wait till your Drs have to buy Prolia for $825 and see what they say. I will be telling them about the amount of time they have to wait for reimbursement. That is they get reimbursed at all!
 






Anonymous said:
Hey dumbfuck, I f-ing sold reclast and it's not $1150 anymore, especially where I live. They have had two price increases since launch where it was originally priced at around $1150 2 1/2 years ago, dumbass. I have done pharmacy checks and it is priced right at $1400 plus the infusion fees which in my market averages out to be another $75. FU
Click to expand...

Ahhhh....the quality, reasoned response of the former Novartis schmuck now a biotech specialist with Amgen....let's ask him how he feels about losing his summer break and see what happens....
 






Anonymous said:
Ignorant dumb fuck..... what fuckin pharmacy checks you are talking? Reclast AWP is available publicly...redbook, thomson reuters databank etc

just read the comments from one specialist in the article as I am sure you don't have access to any of the shit i mentioned above

http://seekingalpha.com/article/207...ly-to-early-fda-approval-of-osteoporosis-drug
Click to expand...


Ah, if I had a dollar for every time the word, F--K is mentioned in all these posts, I wouldn't have to own Amgen's frustrating stock.
 






Anonymous said:
Well, I don't know you ill-informed idiot! Reclast is $1500+ a year and it's Novartis fastest growing launch product ever. I know, I launched it 2 1/2 years ago. I'll put this in lamen's terms so you have a slight chance of understanding it...Medicare Part B is the patient that we are going after, just like Reclast. Med B pays 80% of the cost right off the top, then over 90% of Med B pts also have a supplemental coinsurance that picks up almost all of the remaining 20% cost. It's June, an extremely high % of Medicare pts have already met and paid their respective deductibles. So guess what, for the Med B pts (which I stated is the pts that we are going after) will have a co-pay under that of branded orals and real damn close to generic alendronate. Got it? Unbelievable how stupid some people are spouting off. I lived in the Reclast, Med B world for 2 1/2 years and as soon as you get around any kind of paperwork for insurance verification, then the price point isn't that much of an issue for the Med B pts. By the way, our paperwork up front and throughout the process is much more simplified than Reclast for sure. So believe what you will but just know that you are way off base.
Click to expand...

Prolia is self inj. Its part D. We will compete with orals
 






No, it's not. It is to be injected by a health professional. Prolia can be used under medical benefits and also the pharmacy benefit. But you already knew that. Although you do not work here.
 












Top Bottom
Back
Quote